<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03858426</url>
  </required_header>
  <id_info>
    <org_study_id>RENESE</org_study_id>
    <nct_id>NCT03858426</nct_id>
  </id_info>
  <brief_title>Prospective Multicenter Nationwide Registry of Children With Eosinophilic Esophagitis</brief_title>
  <acronym>RENESE</acronym>
  <official_title>Prospective Multicenter Nationwide Registry of Children With Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sociedad Espanola de Gastroenterologia, Hepatologia y Nutricion Pediatrica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sociedad Espanola de Gastroenterologia, Hepatologia y Nutricion Pediatrica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Registry of demographic, clinical, endoscopic and histological data at baseline.

        2. Registry of patients treated with PPI:

             -  Clinical, endoscopic and histological response at 8-12 weeks of induction treatment

             -  Clinical, endoscopic and histological response at 6 and 12 months weeks of
                maintenance treatment

        3. Registry of patients treated with two foods elimination diet:

             -  Clinical, endoscopic and histological response at 8-12 weeks of induction treatment

             -  Identification of food trigger: milk, gluten or milk and gluten

             -  Clinical, endoscopic and histological response at one year elimination of food
                trigger

             -  Registry of adverse events

        4. Registry of patients treated with swallowed steroids (budesonide or fluticasone):

             -  Clinical, endoscopic and histological response at 8-12 weeks of induction treatment

             -  Clinical, endoscopic and histological response at 6 months of maintenance steroid
                treatment

             -  Registry of adverse events
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Complete histological remission</measure>
    <time_frame>12 weeks</time_frame>
    <description>Complete histological remission response defined as ≤5 eosinophils/hpf in all biopsies performed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial histological remission</measure>
    <time_frame>12 weeks</time_frame>
    <description>Partial histological remission response defined as 5-15 eosinophils /hpf in all biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinical remission (specific questionnaire)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>Children with eosinophilic esophagitis</arm_group_label>
    <description>Inclusion criteria:
Children from 1 month to 18 years with a new diagnosis of eosinophilic esophagitis according to recent European guidelines (symptoms of esophageal dysfunction + eosinophilic infiltrate of the esophagus &gt; 15 eos / CGA)
And they need to start treatment with one of the following options: PPI, diet excluding cow's milk and gluten, or swallowed corticosteroids
Exclusion criteria:
Presence of pathological eosinophilia at the gastric or duodenal level (eosinophilic gastroenteritis)
Simultaneous treatment with more than one treatment modality (PPI, empirical elimination diet, swallowed corticosteroids).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention</description>
    <arm_group_label>Children with eosinophilic esophagitis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children from 1 month to 18 years with a new diagnosis of eosinophilic esophagitis
        according to the recent European guidelines
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children from 1 month to 18 years with a new diagnosis of eosinophilic esophagitis
             (EoE) according to the recent European guidelines (symptoms of esophageal dysfunction
             + eosinophilic infiltrate of the esophagus &gt; 15 eos / CGA)

          -  And that they need to start treatment with any of the following options: PPI, diet
             excluding cow's milk and gluten, or swallowed corticosteroids .

        Exclusion Criteria:

          -  Presence of pathological eosinophilia at the gastric or duodenal level (eosinophilic
             gastroenteritis)

          -  Simultaneous treatment with more than one treatment modality (PPI, empirical
             elimination diet, swallowed corticosteroids).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Carolina Gutierrez-Junquera, MD, PHD</last_name>
    <phone>+34911916437</phone>
    <email>carolina.gutijun@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Belén Ruiz-Antorán, MD, PHD</last_name>
    <phone>+34911917479</phone>
    <email>mariabelen.ruiz@salud.madrid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Gutierrez Junquera, PhD</last_name>
      <phone>911916437</phone>
      <email>carolina.gutijun@salud.madrid.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>February 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2019</study_first_posted>
  <last_update_submitted>February 26, 2019</last_update_submitted>
  <last_update_submitted_qc>February 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sociedad Espanola de Gastroenterologia, Hepatologia y Nutricion Pediatrica</investigator_affiliation>
    <investigator_full_name>Carolina Gutierrez Junquera</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Eosinophilic Esophagitis; PPIs, children, elimination diet, topical steroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

